Your Medication Isn't Working. Your Genes May Know Why.

CYP2D6 is one of your liver’s most important drug-processing enzymes. It breaks down antidepressants (SSRIs, tricyclics), opioids, beta-blockers, antipsychotics, and pain medications. If CYP2D6 works efficiently, medications reach therapeutic levels in your bloodstream at the standard dose. If it doesn’t, drugs either pile up (causing side effects) or are eliminated so fast that you get no benefit.

CYP2D6 has multiple variants that make it slower or faster, and some people carry gene duplications that make it extremely fast. Poor metabolizers, who carry *2, *4, *10, or *17 variants, represent roughly 7-10% of people with European ancestry. Poor metabolizers can experience toxic drug accumulation at standard doses, leading to severe side effects or hospitalizations. Ultra-rapid metabolizers may need 2-3 times the standard dose to feel any effect.

You might experience this as taking an antidepressant at the prescribed dose and becoming sedated, confused, or developing tremors within days. Or you might take the same medication and feel absolutely nothing, then your doctor increases the dose, and you still feel nothing, because your body is eliminating it too quickly. Either scenario points to CYP2D6 variation.

CYP2C19 metabolizes clopidogrel (a blood thinner), proton pump inhibitors (PPIs), and many antidepressants including sertraline and escitalopram. It’s especially important for people on clopidogrel after a stent placement or stroke prevention, because clopidogrel is a prodrug, meaning your body has to activate it before it works.

Poor metabolizers carry *2 or *3 variants and account for roughly 2-15% of the population depending on ancestry (higher in Asian populations). If you’re a poor CYP2C19 metabolizer taking clopidogrel, the drug never gets activated, and you get zero antiplatelet protection. This is clinically dangerous. In contrast, ultra-rapid metabolizers (carrying the *17 variant) may metabolize the drug so quickly they have an elevated bleeding risk.

You might experience this as a cardiologist prescribing clopidogrel after your stent, but you continue having clotting events because the medication never activated. Or you take an SSRI at the standard dose and feel nothing for weeks, then your doctor keeps raising it, not realizing your body simply can’t metabolize it efficiently.

CYP2C9 metabolizes warfarin (a blood thinner), NSAIDs like ibuprofen, and some statins. It’s most clinically significant for warfarin dosing, because warfarin has a narrow therapeutic window. Too little and you clot; too much and you bleed. Your CYP2C9 status directly determines your safe warfarin dose.

Poor metabolizers carry *2 or *3 variants and represent roughly 5-10% of European ancestry populations. Poor CYP2C9 metabolizers accumulate warfarin to dangerous levels on standard doses and have a significantly elevated risk of bleeding. Standard dosing algorithms don’t account for this, which is why some people on warfarin suddenly develop bleeding complications while others on the same dose are fine.

You might experience this as taking warfarin at the dose your doctor prescribed, feeling fine for a few weeks, then suddenly noticing bruising, blood in urine, or nosebleeds that won’t stop. You go to the ER, your INR (international normalized ratio) is dangerously high, and your doctor lowers your dose. Without knowing your CYP2C9 status, this becomes a guessing game every time you take the medication.

VKORC1 encodes vitamin K epoxide reductase, an enzyme that recycles vitamin K in your body. Warfarin works by blocking this enzyme, which lowers your blood clotting factors. But VKORC1 variants change how sensitive this enzyme is to warfarin’s effects. If you have a variant that makes your enzyme less responsive to warfarin, you need higher doses. If you have a variant that makes it more responsive, you need lower doses.

The -1639G>A variant is common, with the A allele present in roughly 40% of people with European ancestry. VKORC1 A allele carriers have reduced vitamin K recycling and are highly sensitive to warfarin, requiring roughly 20-50% lower doses than average. This is independent of your CYP2C9 status; they work together to determine your total warfarin need.

You might experience this as your doctor prescribing a standard warfarin dose, and you develop bleeding immediately, or your INR swings wildly with small dietary changes in vitamin K. Conversely, if you have the G allele, standard doses might not give you enough anticoagulation, and you might clot despite being on warfarin.

SLCO1B1 encodes a transporter that pulls statins into your liver cells so they can do their job (lowering cholesterol). Without efficient SLCO1B1 function, statins stay in your bloodstream longer and at higher concentrations, increasing the risk of muscle pain and breakdown (statin-induced myopathy).

The rs4149056 C allele variant reduces SLCO1B1 function and is present in roughly 15% of the population. SLCO1B1 C allele carriers have reduced statin uptake into liver cells, meaning systemic statin exposure is elevated, dramatically increasing the risk of myopathy at standard doses, especially with simvastatin. This effect is dose-dependent but can occur even at moderate doses in genetically susceptible people.

You might experience this as taking simvastatin for cholesterol and developing muscle pain, weakness, or dark urine (signs of myoglobin in urine, indicating muscle breakdown). Your doctor checks your liver enzymes and they look normal, so they blame the statin and switch you to a different one. But the real problem is that you genetically accumulate statins in your bloodstream at higher concentrations.

TPMT metabolizes thiopurine drugs like azathioprine and 6-mercaptopurine, which are used for autoimmune diseases and leukemia. These drugs are pro-drugs that your body converts into active metabolites. If TPMT is efficient, you produce the right amount of active drug. If TPMT is slow, toxic metabolites accumulate, causing severe bone marrow suppression and infections.

TpMT poor metabolizers represent roughly 0.3% of the population, but they’re at extreme risk. TPMT poor metabolizers accumulate toxic thiopurine metabolites at standard doses and face a life-threatening risk of bone marrow suppression, infection, and death. This is why TPMT testing is actually recommended before starting thiopurine therapy in most modern clinics.

You might experience this as starting azathioprine for lupus or inflammatory bowel disease at the standard dose, and within weeks developing severe infections, unexplained bruising, or blood count crashes. Emergency room doctors may not realize that a genetic variant, not a side effect of the drug itself, is the problem. Without pre-test knowledge of your TPMT status, this can be fatal.